ストックスクリーナーアプリを入手
3.52
4.22%
-0.155
アフターアワーズ：
3.53
0.010
+0.28%
前日終値:
$3.675
開ける：
$3.73
24時間の取引高:
19,721
Relative Volume:
0.63
時価総額：
$10.46M
収益：
-
当期純損益:
$2.81M
株価収益率:
-0.3822
EPS:
-9.2108
ネットキャッシュフロー:
$7.14M
1週間 パフォーマンス:
-8.57%
1か月 パフォーマンス:
+1.88%
6か月 パフォーマンス:
-23.80%
1年 パフォーマンス:
-36.93%
1日の値動き範囲:
$3.52
$3.75
1週間の範囲:
$3.46
$3.85
52週間の値動き範囲:
$3.00
$8.982
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
名前
Kiora Pharmaceuticals Inc
セクター
電話
781-788-8869
住所
332 ENCINITAS BOULEVARD, ENCINITAS
Kiora Pharmaceuticals Inc (KPRX) 最新ニュース
Kiora Pharmaceuticals Gains Approval for Phase 2 Trial - Yahoo Finance
Kiora Pharmaceuticals advances phase 2 trial for vision restoration By Investing.com - Investing.com Canada
Kiora Pharmaceuticals advances phase 2 trial for vision restoration - Investing.com
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa - Yahoo Finance
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences - MSN
Kiora Pharmaceuticals director buys shares worth $4,600 - Investing.com
Kiora Pharmaceuticals director Shapiro Aron buys $10,800 in company stock - Investing.com
Kiora Pharmaceuticals (NASDAQ:KPRX) Receives “Buy” Rating from HC Wainwright - Defense World
Kiora Pharmaceuticals director buys $19.8k in company stock By Investing.com - Investing.com Australia
Kiora Pharmaceuticals director buys $19.8k in company stock - Investing.com India
Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Up 15.7% - Defense World
How To Buy Kiora Pharmaceuticals, Inc. Stock Online in August 2024 - Traders Union
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies - Yahoo Finance
KPRXKiora Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Kiora Pharmaceuticals receives Orphan Medicinal Product Designation for KIO-301 - Ophthalmology Times Europe
Kiora Pharmaceuticals gains EMA orphan drug status for IRD treatment By Investing.com - Investing.com Canada
Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies - Newsfile
HC Wainwright Brokers Decrease Earnings Estimates for Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) - Defense World
Kiora Pharmaceuticals (NASDAQ:KPRX) Price Target Increased to $10.00 by Analysts at HC Wainwright - Defense World
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Up 11.6% in June - Defense World
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Quantisnow
Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation - StockTitan
Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Down 0.9% - Defense World
EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Quantisnow
Kiora Pharmaceuticals appoints new board member By Investing.com - Investing.com
Sezzle Inc. former director Purcell sells shares worth over $1.29 million By Investing.com - Investing.com Australia
Vivakor nears acquisition of oil and gas logistics firms By Investing.com - Investing.com Canada
Kiora Pharmaceuticals Announces Board Appointment, Regains Nasdaq Compliance - TipRanks
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors - StreetInsider.com
Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board - Newsfile
Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory ... - StockTitan
CBRE to merge Project Management with Turner & Townsend By Investing.com - Investing.com UK
Global Payments shares price target cut by TD Cowen amid controversy By Investing.com - Investing.com
KPRX Stock Price and Chart — NASDAQ:KPRX - TradingView
Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in ... - Quantisnow
Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress - Quantisnow
Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now? - Yahoo Finance
Kiora Pharmaceuticals (NASDAQ:KPRX) Upgraded to Strong-Buy at Maxim Group - Defense World
Brian M. Strem Buys 3000 Shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Stock - Defense World
NorthWest Healthcare Properties Real Estate Investment Trust (TSE:NWH) Declares Monthly Dividend of $0.03 - Defense World
Kiora Pharmaceuticals EVP finance buys shares worth $525Investing.com ZA - Investing.com South Africa
Erin Parsons Purchases 5260 Shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Stock - Defense World
Kiora Pharmaceuticals exec buys $7.6k in company stock - Investing.com India
Kiora Pharmaceuticals EVP finance buys shares worth $525 By Investing.com - Investing.com
Kiora Pharmaceuticals exec buys $7.6k in company stock By Investing.com - Investing.com Australia
Kiora Pharmaceuticals CEO acquires $14.9k in company stock By Investing.com - Investing.com Australia
Kiora Pharmaceuticals Inc (KPRX) 財務データ
収益
当期純利益
現金流量
EPS
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):